The U.S. holds the lionâ€™s share (38%) of the market for devices and therapies related to diabetes management. There are roughly 18 million Americans that have been diagnosed with diabetes and another 6 million remain undiagnosed, according to the American Diabetes Association. Further, it is estimated that 1.6 million new cases of diabetes are diagnosed each year among people aged 20 years and older. A large factor in the rising prevalence of diabetes in America is an alarming rapid increase in obesity. Obesity is a proven major risk factor for cardiovascular disease, some types of cancer and type 2 diabetes.
Unfortunately, as the rate of obesity increases, so does the rate of diabetes. As such, the market for therapies to treat this disease will continue to have strong growth over the several years at least.
Diabetes management involves (in varying amounts for types 1 & 2) glucose monitoring (standard, continuous), lancets, test strips, insulin, insulin pumps, syringes and other insulin delivery, and anti-diabetic drugs. Â These products are at different price points, use rates, and market growth.
The graphic shows, by bubble size and position, the market size and compound growth (to 2018) for each. Data is drawn from the MedMarket Diligence report #D510, “Diabetes Management: Products, Technologies, Markets and Opportunities Worldwide 2009-2018.”